Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triptorelin pamoate
Drug ID BADD_D02298
Description Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
Indications and Usage Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Marketing Status Prescription
ATC Code L02AE04
DrugBank ID DB06825
KEGG ID D06248
MeSH ID D017329
PubChem ID 25074469
TTD Drug ID D03QRS
NDC Product Code 71161-104; 0023-5902; 0023-5906; 71161-105; 0023-5904; 74676-5906; 71161-103; 74676-5904; 55463-0006; 74676-5902
Synonyms Triptorelin Pamoate | Pamoate, Triptorelin | Triptorelin Embonate | Embonate, Triptorelin | CL-118532 | CL 118532 | CL118532 | Trelstar | Triptorelin | LHRH, Trp(6)- | GnRH, Trp(6)- | LHRH, Tryptophyl(6)- | D-Trp-6-LH-RH | 6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig) | Wy-42462 | Wy 42462 | Wy42462 | AY-25650 | AY 25650 | AY25650 | Decapeptyl | Decapeptyl Trimestral | Trimestral, Decapeptyl | Decapeptyl LP | Decapeptyl Depot
Chemical Information
Molecular Formula C87H98N18O19
CAS Registry Number 124508-66-3
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32) NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7 )NC(=O)C8CCC(=O)N8.C1=CC=C2C(=C1)C=C(C(=C2CC3=C(C(=CC4=CC=CC=C43)C(=O)O)O)O)C(=O )O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertension24.08.02.001--
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Libido decreased21.03.02.005; 19.08.03.001--
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nausea07.01.07.001--
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Rash23.03.13.001--Not Available
Red blood cell count13.01.05.020--Not Available
Thrombophlebitis24.01.02.001--Not Available
Transient ischaemic attack24.04.06.005; 17.08.04.001--
Urinary tract infection20.08.02.001; 11.01.14.004--
Pituitary haemorrhage17.08.01.019; 05.03.04.005; 24.07.04.009--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Affect lability19.04.01.001--Not Available
Transaminases increased13.03.01.015--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Urinary tract obstruction20.08.01.004--
Nail atrophy23.02.05.010--Not Available
The 2th Page    First    Pre   2    Total 2 Pages